Intellia Therapeutics (NASDAQ:NTLA) Given New $91.00 Price Target at Chardan Capital

Intellia Therapeutics (NASDAQ:NTLA) had its price target lifted by Chardan Capital from $88.00 to $91.00 in a research note published on Monday,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

A number of other equities research analysts also recently weighed in on the company. The Goldman Sachs Group lowered their price target on Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Barclays decreased their price objective on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. StockNews.com raised Intellia Therapeutics to a “sell” rating in a research note on Friday, November 8th. Stifel Nicolaus decreased their price target on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a research note on Wednesday, September 11th. Finally, Robert W. Baird decreased their target price on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Intellia Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $54.94.

Intellia Therapeutics Stock Down 7.1 %

Intellia Therapeutics stock opened at $13.12 on Monday. The business has a 50-day simple moving average of $18.40 and a 200 day simple moving average of $21.91. Intellia Therapeutics has a 52 week low of $12.82 and a 52 week high of $34.87. The stock has a market cap of $1.34 billion, a price-to-earnings ratio of -2.41 and a beta of 1.81.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.03. The company had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. The firm’s revenue for the quarter was down 24.1% on a year-over-year basis. During the same quarter last year, the company posted ($1.38) earnings per share. On average, research analysts anticipate that Intellia Therapeutics will post -5.13 earnings per share for the current year.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the transaction, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. This trade represents a 4.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Blue Trust Inc. boosted its position in shares of Intellia Therapeutics by 1,664.3% in the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock worth $33,000 after purchasing an additional 1,398 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in Intellia Therapeutics by 763.5% during the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after buying an additional 1,550 shares during the last quarter. Eastern Bank purchased a new position in Intellia Therapeutics during the third quarter valued at $41,000. First Horizon Advisors Inc. boosted its holdings in Intellia Therapeutics by 22.1% in the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after acquiring an additional 472 shares in the last quarter. Finally, Values First Advisors Inc. purchased a new stake in shares of Intellia Therapeutics in the third quarter worth $54,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.